Sartorius Stedim Biotech has completed a comprehensive multi-year expansion of its manufacturing and R&D capabilities at its headquarters in Aubagne, France, positioning the company to meet surging demand for single-use bioprocessing solutions used in biopharmaceutical manufacturing. The project, launched in 2021, represents a significant investment in advanced bioprocessing technologies that support the production of cell and gene therapies.
Expanded Manufacturing Capabilities
The expansion nearly doubled the company's cleanroom space to approximately 9,000 square meters, featuring automated and digitized production lines for both 2D and 3D single-use bags. These bags are critical components in biopharmaceutical manufacturing, used for cell culture, storage, and shipping of fluids throughout the production process.
"By investing in innovation, automation, and sustainability, we are strengthening our ability to meet the evolving needs of our customers while ensuring our competitive positioning and preparing for future growth," said René Fáber, CEO of Sartorius Stedim Biotech. "This emphasizes our commitment to simplify and accelerate progress in bioprocessing with advanced technologies, enabling new and better therapies to be manufactured faster, more efficiently and more sustainably."
The new automated production lines are designed to increase both productivity and reliability in manufacturing single-use bioprocessing solutions, addressing the growing market demand for these technologies in biopharmaceutical production.
Advanced Logistics and Warehouse Operations
A key component of the expansion is a new 12,000-square-meter high-bay warehouse optimized for efficient pallet processing. The facility incorporates autonomous forklifts and mobile robots that streamline operations using a Goods-To-Person approach, allowing operators to focus on specialized tasks. This automated logistics facility is designed to accelerate raw material handling for single-use bag manufacturing and will be fully operational by fall 2025.
Enhanced R&D and Customer Collaboration
The expanded site includes a new 1,900-square-meter cross-functional laboratory space that opened to customers in early 2024. This facility is designed to enhance collaboration between internal teams and external partners, housing product development labs for fluid management and cell culture technologies, as well as application labs for customer demonstrations and training.
The laboratory expansion reflects the company's commitment to innovation in bioprocessing technologies and provides enhanced capabilities for developing next-generation solutions for biopharmaceutical manufacturing.
Sustainability and Environmental Standards
The expansion incorporates significant sustainability measures, with the site achieving ISCC Plus certification for using renewable raw materials in plastic component production, substantially reducing the share of fossil-based materials in products. The company has also adopted ISO 14001 environmental management standards to improve environmental performance and reduce the ecological footprint of operations.
The new buildings have earned HQE® Excellent and BiodiverCity® certifications for sustainable construction and biodiversity measures, demonstrating the company's commitment to environmental responsibility in its expansion efforts.
Significant Growth and Investment
The total area of the Aubagne premises has quadrupled to around 90,000 square meters since 2020. The expansion includes a modern office building at the center of the campus, featuring a showroom, conference center, restaurant, and gym facilities.
Since 2021, Sartorius Stedim Biotech has made substantial investments across its French operations, including facilities in Lourdes, Cergy, Pompey, and Strasbourg. The company now employs approximately 1,400 people across seven sites in France, with more than 1,100 based in Aubagne. Over the past decade, the company's French workforce has approximately doubled.
Sartorius Stedim Biotech generated sales revenue of around 2.8 billion euros in 2024 and currently employs more than 9,900 people globally, serving customers in the biopharmaceutical industry with solutions for manufacturing biotech medications, including cell and gene therapies.
